{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:22:14Z","timestamp":1768818134561,"version":"3.49.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Waldenstrom\u2019s macroglobulinemia (WM) is a rare and indolent B-cell lymphoma. To investigate the type and survival of hematologic secondary malignancies (SMs) in Chinese patients with WM, we retrospectively reviewed the characteristics of 102 patients with WM from February 2002 to May 2023 in our center. Four men and two women were diagnosed with hematologic SMs. Of the six patients with hematologic SMs, one was diagnosed with acute myeloid leukemia (AML), one with multiple myeloma (MM), one with myelodysplastic syndrome (MDS), one with B-cell acute lymphoblastic leukemia (B-ALL), and two with diffuse large B-cell lymphoma (DLBCL). The median age was 65.5 years (56\u201374 years). The median interval time between diagnosis of WM and hematologic SMs was 39.5 months (10\u2013117 months). Among those with WM with hematologic SMs, five died and one survived. Overall survival (OS) was just 33 months (12\u2013119 months) on median. A total of 32 patients died and 64 survived in the group of WM without hematologic SMs, and the median OS was 82 months (3\u2013250 months). This is the first study in the Chinese population on hematologic SMs in WM. The purpose of this study was to investigate the prognosis of hematologic SMs in WM in the Chinese population, as well as to compare the population\u2019s characteristics to those of other centers. We investigated the underlying causes further and presented a research strategy for our forthcoming investigation. We intend to investigate risk factors for SMs as well as more accessible screening methods.<\/jats:p>","DOI":"10.3389\/fonc.2023.1280033","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:47:05Z","timestamp":1701067625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hematologic secondary malignancies among 102 Chinese patients with Waldenstrom\u2019s macroglobulinemia: a single-center case experience and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Lingling","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conglin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia-A British Society for Haematology guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3816\/CLML.2011.n.016","article-title":"Associated Malignancies in patients with Waldenstr\u00f6m's macroglobulinemia and their kin","volume":"11","author":"Hanzis","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr537","article-title":"Second Malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data","volume":"23","author":"Ojha","year":"2012","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Varettoni","year":"2012","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary Malignancies among patients with Waldenstr\u00f6m macroglobulinemia: An analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26507","article-title":"Expression of p53 protein isoforms predicts survival in patients with multiple myeloma","volume":"97","author":"Rojas","year":"2022","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18410","article-title":"Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome","volume":"199","author":"De Ram\u00f3n","year":"2022","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second Malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25706","article-title":"Risk of second cancer after lymphohematopoietic neoplasm","volume":"129","author":"Royle","year":"2011","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other Malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33454","article-title":"Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenstr\u00f6m macroglobulinemia","volume":"127","author":"Wan","year":"2021","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1280033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:47:07Z","timestamp":1701067627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1280033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":18,"alternative-id":["10.3389\/fonc.2023.1280033"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1280033","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"article-number":"1280033"}}